ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Scientists Glimpse Cellular Machines Inside Living Cells; Funding Opportunities

November 22, 2002

PDQ Now Offers CME Credit to Physician Users

July 3, 1987

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer

December 27, 2002

In Brief: NCAB Objects To Low Priority For Several Cancer Control Grants, Asks For New Review

June 22, 1979

Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed

December 12, 1975